PRS

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
星期一, 三月 25, 2024
Human Genome Project, WGS, Blood pressure, Genomics, Health, Certification, Informatics, Founders Fund, Genetic testing, Risk, Genetics, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1

NEW YORK, March 25, 2024 /PRNewswire/ -- Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer's entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina's NovaSeq X Plus, the sequencing company's newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Allelica to provide multi-ancestry polygenic risk score to Baylor College of Medicine for clinical implementation

Retrieved on: 
星期二, 三月 19, 2024
WGS, Health informatics, Informatics, Coronary artery disease, Associate, Patient, PRS, ASHG, Human genetics, Laboratory, Whole genome sequencing, Baylor College of Medicine, Society, Traction, BCM, Physician, Health

NEW YORK, March 19, 2024 /PRNewswire/ -- Allelica, market leader in clinical solutions for polygenic risk score analysis and reporting, has announced a strategic collaboration with leading health sciences institution, Baylor College of Medicine (BCM), to integrate clinical, multi-ancestry polygenic risk score (PRS) testing into BCM's extensive patient services portfolio.

Key Points: 
  • NEW YORK, March 19, 2024 /PRNewswire/ -- Allelica, market leader in clinical solutions for polygenic risk score analysis and reporting, has announced a strategic collaboration with leading health sciences institution, Baylor College of Medicine (BCM), to integrate clinical, multi-ancestry polygenic risk score (PRS) testing into BCM's extensive patient services portfolio.
  • This marks a significant milestone in making world class genomic medicine accessible, equitable, and impactful for patients across diverse communities.
  • Allelica's PRS solution enables more precise identification of patients' genetic risk for coronary artery disease and other diseases and traits.
  • Baylor is one of several institutions working with Allelica to provide clinical PRS testing to patients.

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
星期三, 三月 6, 2024
Radiation, Doctor of Philosophy, Immunotherapy, News, FOLFIRINOX, Growth, CADL, PR, CXCR4, Lead, PRS, Multiple myeloma, Poster, Pancreatic cancer, Gemcitabine, Fast Track, Liver, Incidence, Cancer, City, HSC, Chung, TME, Overalls, FACP, Therapy, Sickle cell disease, Columbia University, MAPK, Immune system, SNF, G-CSF, Woman, AIO, SCD, AACR, PD-1, Conference, TILS, Tumor microenvironment, BioLineRx, Clinical trial, Survival, Oncology, Filgrastim, Collection, American Cancer Society, Caregiver, USD, SWI, MD, Blood, FDA, TSX, Biotechnology, Pancreatic Cancer Action Network, Stem cell, RAS, Valaciclovir, PDAC, Patient, Natalizumab, ONC, PEI, Pharmaceutical industry

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

23andMe Launches New Genetic Reports on Common Forms of Cancer

Retrieved on: 
星期三, 三月 6, 2024
African Americans, SAN, Breast cancer, American Cancer Society, Cancer, Breast, 23andMe, Health, Genetics, Genomic Health, Database, PRS, Genetic, Patient, Black, Disease, Machine learning, Colorectal cancer, Premium, Research, Prostate cancer, Dietary supplement

The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.

Key Points: 
  • The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.
  • Availability of the breast cancer and prostate cancer PRS reports is based on self-reported birth sex.
  • The PRS models on which the new 23andMe reports are based were developed using the 23andMe database, and further validated using an external database.
  • To learn more about the new 23andMe PRS reports on cancer, and becoming a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Retrieved on: 
星期三, 二月 28, 2024
Cetuximab, Research, Castration, PRS, Intellectual property, Patient, Pancreatic cancer, HNSCC, EAP, Eli Lilly and Company, CRPC, Drug design, BLA, FTD, HER2, MET, Congress, Afatinib, Partnership, NSCLC, CD3, EGFR, ESMO, BTD, Betta, CRC, AACR, Safety, Biomarker, RECIST, Clinical trial, Oncology, Prostate cancer, Neoplasm, FDA, Pembrolizumab, Lung, Disease, Travel, Pharmaceutical industry

Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.

Key Points: 
  • Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
  • Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
  • Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.

Saucony® Signs Pro Runner Vanessa Fraser

Retrieved on: 
星期五, 三月 8, 2024
Love, Scotts Valley High School, Foot, Stanford University, Endorphins, History, PRS, Running, Nightclub

ROCKFORD, Mich., March 8, 2024 /PRNewswire/ -- Global performance running lifestyle brand Saucony is further solidifying its commitment to elevating women's and girl's participation in running with the signing of pro runner Vanessa Fraser. A seven-time All-American from Stanford University, Fraser, 27, has set personal bests in the 3,000m indoors (8:51); 5,000m indoors (14:48); 10,000m (31:52); and half marathon (1:11:00). Fraser, who turned pro in 2018, is currently based in San Francisco and trains with Team Boss, an elite distance running team located in Boulder, Colorado.

Key Points: 
  • ROCKFORD, Mich., March 8, 2024 /PRNewswire/ -- Global performance running lifestyle brand Saucony is further solidifying its commitment to elevating women's and girl's participation in running with the signing of pro runner Vanessa Fraser.
  • A seven-time All-American from Stanford University, Fraser, 27, has set personal bests in the 3,000m indoors (8:51); 5,000m indoors (14:48); 10,000m (31:52); and half marathon (1:11:00).
  • Fraser, who turned pro in 2018, is currently based in San Francisco and trains with Team Boss, an elite distance running team located in Boulder, Colorado.
  • "Vanessa joins the Saucony roster as a world-class talent with unlimited potential," said Ted FitzPatrick, Saucony's vice president of product and sports marketing.

BeeHero Launches Pollination Research Stations to Give Growers and Stakeholders Real-Time Visibility Into Bees & Pollination

Retrieved on: 
星期三, 二月 28, 2024
Bee, Research, Health, Weather, AI, Arm, PRS, Life, Entrepreneurship, Pollination, Frost, CNBC, Agriculture, Science

FRESNO, Calif., Feb. 28, 2024 /PRNewswire/ -- BeeHero, the pioneer of data-driven precision pollination, today announced the launch of its groundbreaking Pollination Research Stations (PRS). With three Pollination Research Stations situated in California's Central Valley, BeeHero's innovative data platform now provides unprecedented ability to track and monitor bloom progress and bee activity in the world's most important almond-producing region.

Key Points: 
  • Approximately 75% of crops grown for human consumption rely on pollination, underscoring the process's critical role in global food security.
  • Understanding pollination progress is essential for effective pollination, as it allows growers to optimize their timing and allocate resources efficiently to best sustain their agricultural operations and maximize yield potential.
  • BeeHero's Pollination Research Stations deliver real-time, accurate, and extensive data on bloom progression and bee activity, providing unprecedented visibility for growers who previously operated with minimal data.
  • BeeHero's Research Pollination Stations live updates can be seen here: https://growers.beehero.io/ExternalsentinelStations .

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Retrieved on: 
星期三, 二月 28, 2024
Liver, Collection, Immunotherapy, FDA, TEL, Pancreatic cancer, HSC, SCD, Stem cell, AACR, PD-1, Conference, CXCR4, Lead, PDAC, PRS, BioLineRx, Patient, Sickle cell disease, Multiple myeloma, Columbia University, Filgrastim, Natalizumab, Cancer, Gemcitabine, Pharmaceutical industry

TEL AVIV, Israel, Feb. 28, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). The investigator-initiated trial is being conducted in collaboration with Columbia University and is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.

Key Points: 
  • The investigator-initiated trial is being conducted in collaboration with Columbia University and is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.
  • "We are encouraged by our early pilot data and look forward to continuing to advance the expanded, randomized Phase 2 CheMo4METPANC trial for patients living with this cancer."
  • The findings were previously presented during an oral presentation at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston, Massachusetts, September 28, 2023.
  • Motixafortide is also being evaluated in a Phase 1 clinical trial evaluating motixafortide as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD).

Virsys12 Boosts Healthcare Operations with New Provider Data Management Features

Retrieved on: 
星期二, 二月 27, 2024
Consensus, Directory, Completeness, CMS, Record, Data management, NetworkManager, Government, CAQH, SAAS, PRS, ViVe, NPI, TIN, Salesforce, Data Age, PDE

BRENTWOOD, Tenn., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Virsys12, a leading provider of solutions for provider network management and ongoing provider data management and directory updates, today announced at the ViVE conference in Los Angeles, CA, new features in its flagship SAAS applications, V12 Network and V12 Provider Data Engine (PDE). With its robust and scalable platform, Virsys12 continues to empower healthcare organizations to eliminate inefficiencies in their provider data management and workflow processes.

Key Points: 
  • BRENTWOOD, Tenn., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Virsys12 , a leading provider of solutions for provider network management and ongoing provider data management and directory updates, today announced at the ViVE conference in Los Angeles, CA, new features in its flagship SAAS applications, V12 Network and V12 Provider Data Engine (PDE) .
  • With its robust and scalable platform, Virsys12 continues to empower healthcare organizations to eliminate inefficiencies in their provider data management and workflow processes.
  • Custom Data Field Mapping: Update provider data based on "groupings," increase data auditability, and implement manual or automatic data override functionality.
  • "This application processes data from various provider data sources, including provider demographics, provider taxonomies and specialties, and practicing location (both master address location data and practitioner address data).

Two thirds of PR Pros can't prove their work helps their business or client: CoverageBook

Retrieved on: 
星期四, 二月 22, 2024
Well, Cision, AVE, Marketing, Work, Google Sheets, PR, PRS, Microsoft Excel, CIPR, Public, Research, Face

New research from CoverageBook , the leading PR industry reporting platform, shows that just one third of PR pros align their activity with commercial goals.

Key Points: 
  • New research from CoverageBook , the leading PR industry reporting platform, shows that just one third of PR pros align their activity with commercial goals.
  • This research comes at a time when clients are putting increased scrutiny on PR teams to demonstrate impact.
  • To help build that consensus and allow every PR to prove the value of their work, CoverageBook is launching CoverageImpact , a revolutionary free tool designed to simplify PR reporting and impact measurement.
  • The tool is compatible with popular PR tools such as Excel, Google Sheets, Cision, MuckRack, TalkWalker, Meltwater, and CoverageBook, making it accessible to PR professionals worldwide.